Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies
Open Access

Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan

MING-HSIEN WU, CHAO-HSUAN CHEN, CHOU-PIN CHEN, TAI-LIN HUANG, TE-CHENG YUEH, ZHI-HONG WANG, CHIA-WEN TSAI, JEN-SHENG PEI, MEI-CHIN MONG, YA-CHEN YANG, DA-TIAN BAU and WEN-SHIN CHANG
Anticancer Research May 2022, 42 (5) 2375-2382; DOI: https://doi.org/10.21873/anticanres.15716
MING-HSIEN WU
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
2Division of Colon and Rectal Surgery, Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.;
3National Defense Medical Center, Taipei, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHAO-HSUAN CHEN
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
4Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
5Department of Neurosurgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHOU-PIN CHEN
6Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAI-LIN HUANG
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
4Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TE-CHENG YUEH
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
2Division of Colon and Rectal Surgery, Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.;
3National Defense Medical Center, Taipei, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZHI-HONG WANG
7Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIA-WEN TSAI
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
4Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEN-SHENG PEI
8Department of Pediatrics, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEI-CHIN MONG
7Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YA-CHEN YANG
7Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DA-TIAN BAU
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
4Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
9Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
WEN-SHIN CHANG
4Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) is responsible for folate metabolism, and we aimed to investigate its genetic role in colorectal cancer (CRC) among Taiwanese. Materials and Methods: A total of 362 cases and 362 controls were recruited and their MTRR rs1801394 (A66G) and rs1532268 (C524T) genotypes were examined. The behavioral factors and clinicalpathological factors were also analyzed. Results: MTRR rs1801394 genotypes were associated with CRC risk (p for trend=0.0087). In detail, G/G genotype was associated with lower risk (p=0.0049, OR=0.39, 95%CI=0.20-0.76). As for allelic frequency analysis, G allele was also associated with decreased CRC risk (p=0.0026, OR=0.68, 95%CI=0.53-0.88). There was no significant association as for MTRR rs1532268. Among non-smokers and non-alcohol drinkers, those with G/G genotype were at 0.38- and 0.46-fold odds of having CRC. There were no significant protective effects among smokers or alcohol drinkers. Conclusion: MTRR rs1801394 GG genotype can be a protective marker for CRC risk in Taiwan.

Key Words:
  • Colorectal cancer
  • genotype
  • MTRR
  • polymorphism
  • Taiwan

Colorectal cancer (CRC) is the third most common cancer among men and women worldwide (1-3). The incidence and mortality rates of CRC can change as high as ten folds among countries (1, 2, 4). Many factors may contribute to this variation, for instance, meat consumption, cigarette smoking, and exposure to carcinogens contribute to about 85% of CRC etiology (5, 6). In Taiwan, the problem of CRC is rather noticeable. The incidence rate of CRC is number one among all types of cancer, and the mortality rate of CRC is third, just behind lung and liver cancer. As 15-20% of CRC cases have a familial history of cancer (7, 8), genetic factors have been believed to play a very important part in the etiology of CRC. Although some genetic biomarkers for CRC have been revealed during recent years (9-14), however, the interactions between genomic and other risk factors are still of great interest among translational scientists. The understanding of genetic contribution to CRC can help translational scientists to achieve precise medication and therapy.

In the literature, it is demonstrated that folate metabolism has played a critical part in regulating DNA repair capacity and DNA methylation status (15, 16). There were a few famous genetic polymorphic sites of folate metabolism enzymes, including methionine synthase (MTR), methionine synthase reductase (MTRR), and 5,10-methylenetetrahydrofolate reductase (MTHFR). There were also studies reporting that the various genotypes could influence the levels of serum folate (17-19). Consequently, it is biologically plausible that these polymorphisms will affect DNA repair capacity or cause abnormal DNA methylation, which may subsequently lead to gene instability and give rise to development of various kinds of cancers. Among them, MTRR is a vital enzyme involved in folate metabolism. Folate, a water-soluble B-vitamin, is essential for the prevention of malignancy initiation (20). This vitamin functions as a coenzyme in the process of nucleotide synthesis as well as in the DNA and protein methylation (21). The enzymatic activity of MTRR can be affected by a missense MTRR A66G (rs1801394) polymorphisms. A substitution of A to G at the nucleotide 66 changes isoleucine to methionine at position 22 (Ile22Met) of MTRR (22, 23). The MTRR rs1801394 GG genotype is also associated with lower plasma homocysteine concentration compared to the AA genotype (24, 25). Mutation in the gene encoding this enzyme can cause hyper-homo-cysteinemia, which probably contributes to DNA hypomethylation and lowering DNA repair capacity, and leading to CRC initiation (26, 27). MTRR C524T (rs1532268) is considered to be a risk factor for the development of ventricular septal defects (VSD) (28, 29) and gastric cancer (30, 31), but not entirely concluded in CRC risk. Based on the above information, we hypothesized that the variant genotypes at MTRR rs801394 (A66G) and rs1532268 (C524T) may also be involved in determining the personal susceptibility for CRC among Taiwanese. In addition, we will check the genetic-behavioral and genetic-clinical interactions.

Materials and Methods

Collection of 362 CRC cases and 362 control subjects. The CRC cases were recruited as described in our previous studies (13, 14). Briefly and concisely, the CRC cases have been collected, and the pathological data were defined, graded and well recorded. Then, each of the case was well match by age, sex and behaviors including smoking and alcohol drinking. The collection protocols were approved by the Institutional Review Board of the China Medical University Hospital (coding number: DMR99-IRB-108). Specific characters which are analyzed in the study are presented in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Summary of selected data from 362 patients with colorectal cancer and 362 matched non-cancer healthy controls.

MTRR genotyping methodology. The genomic DNA from peripheral blood leukocytes of all participants were extracted and stored at –80°C as previously published (32, 33). The polymerase chain reaction (PCR) conditions set for MTRR genotyping were one cycle at 94°C for 5 min; 35 cycles at 94°C for 30 s, one cycle at annealing 55°C for 30 s and one cycle at elongating 72°C for 30 s and a final extension at 72°C for 10 min. The sequences of forward and reverse primers are designed by Terry Fox Cancer Research Lab and provided in Table II. In addition, the PCR products, corresponding restriction enzymes, and cutting adducts for MTRR rs1801394 and rs1532268 are also presented in Table II.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Information about primers, PCR products, restriction enzymes, and cutting adducts for MTRR rs1801394 and rs1532268.

Statistical analysis. To compare the distribution of MTRR genotypic and allelic distributions between stratified sub-groups, the Pearson’s Chi-square test without Yates’ correction was applied. To check the associations between MTRR genotypes and CRC risk, odds ratios (ORs) together with 95% confidence intervals (CIs) was applied. Adaptation of confounding factors as indicated was applied when examining the interactions of behavioral factors with MTRR genotypes.

Results

Basic indexes between the CRC patient and control groups. The distribution of age, sex and other indexes for the 362 CRC patients and 362 non-cancer healthy controls are shown in Table I. There were 203 (56.1%) males and 159 (43.6%) females both in the CRC case and control groups. Ninety-one (25.1%) of the CRC group had the smoking habits, while 44 (12.2%) had alcohol drinking habits, and the percentages were not significant different from those of the control group (both p>0.05, Table I). The BMI was not differentially distributed between case and control groups (Table I).

Association of MTRR genotypes with CRC risk. The genotypes of MTRR rs1801394 (A66G) and rs1532268 (C524T) among the 362 CRC patients and 362 controls are shown in Table III. First, the various genotypic frequencies of MTRR rs1801394 were differentially distributed between CRC and control groups (p for trend=0.0087). In detail, the MTRR rs1801394 heterozygous A/G and homozygous G/G genotypes were associated with lower risk for CRC than the wild-type A/A genotype (p=0.0825 and 0.0049, OR=0.76 and 0.39, 95%CI=0.55-1.03 and 0.20-0.76). In the recessive model, the G/G genotype conferred a decreased risk for CRC compared to combination of A/A+A/G genotypes (p=0.0110, OR=0.43, 95%CI=0.22-0.84). In the dominant model, those who carry A/G+G/G conferred a decreased susceptibility of CRC compared to the A/A genotype carriers (p=0.0151, OR=0.69, 95%CI=0.51-0.93). On the contrary, as for rs1532268, there was no difference in genotype distribution in any models analyzed (Table III, lower panel). To sum up, the MTRR rs1801394 genotypes play a critical role in determining personal susceptibility to CRC in Taiwan.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Distributions of MTRR rs1801394 and rs1532268 genotypic frequencies among colorectal cancer patients and healthy controls.

The allelic frequency analysis of MTRR with CRC risk. Further analysis of allelic frequency was performed and is presented in Table IV. There is an obvious difference in the distribution of allelic frequencies among the CRC patients and healthy controls regarding MTRR rs1801394 (OR=0.68, 95%CI=0.53-0.88, p=0.0026). On the contrary, there is no difference found as for rs1532268 of MTRR (OR=0.94, 95%CI=0.70-1.27, p=0.7027). This is consistent with the finding in Table III.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Allelic frequencies for MTRR rs1801394 and rs1532268 polymorphisms among the colorectal cancer patients and healthy controls.

Influence of smoking habit and MTRR rs1801394 genotype on CRC risk. Cigarette smoking is a risk factor for Taiwan CRC, we intended to examine the influence of cigarette smoking and MTRR rs1801394 genotypes on CRC risk. As for non-smokers, those with MTRR rs1801394 G/G genotype were at 0.38-fold odds of CRC risk (95%CI=0.18-0.83, p=0.0123). There was no significant association between MTRR rs1801394 A/G genotypes and CRC risk (OR=0.74, 95%CI=0.52-1.07, p=0.1150). After adjusting for age, sex, alcohol drinking and BMI status, the trends are similar for both MTRR rs1801394 G/G and A/G (OR=0.36 and 0.70, 95%CI=0.15-0.80 and 0.48-1.12, respectively). There was no any significant association found among the smokers (Table V).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Odds ratio for MTRR rs1801394 genotype and colorectal cancer after stratification by smoking status.

Influence of alcohol drinking habit and MTRR rs1801394 genotype on CRC risk. Then we aimed to investigate the influence of alcohol drinking and MTRR rs1801394 genotypes on CRC risk, another risk factor for Taiwan CRC. As for those non-drinkers, those with MTRR rs1801394 G/G genotype were at 0.46-fold odds of CRC risk (95%CI=0.22-0.95, p=0.0336). There was no significant association between MTRR rs1801394 A/G genotypes and CRC risk (OR=0.74, 95%CI=0.53-1.03, p=0.0702). After adjusting for age, sex, smoking and BMI status, the trends are similar for both MTRR rs1801394 G/G and A/G (OR=0.42 and 0.71, 95%CI=0.18-0.83 and 0.47-1.02, respectively). There was no any significant association found among the alcohol drinkers (Table VI).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VI.

Odds ratios for MTRR rs1801394 genotype and colorectal cancer after stratification by alcohol drinking status.

Correlations among genotypes of MTRR rs1801394 and clinical indexes. The correlations among genotypes of MTRR rs1801394 and clinical features were analyzed (Table VII). No statistically significant correlation was observed between MTRR rs1801394 genotypic distributions and age, sex, BMI, tumor size or location, or lymph node metastasis status (all p>0.05) (Table VII).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VII.

Correlation between MTRR rs1801394 genotypes and clinicopathological properties of 362 colorectal cancer patients.

Discussion

CRC has been the third most common cause of cancer-related mortality worldwide (1-3), and in Taiwan (35). During the last years, the role of folate and its related genetic variations on CRC have attracted great interest of translational scientists. However, several studies have been conducted, with conflicting findings from various populations with different genetic backgrounds (36-43). Taiwan is genetically and geographically conserved and our collection of CRC cases are representative for Eastern Asia. Our results provided evidence for positive association of MTRR rs1801394 genotypes with CRC risk (Table III and Table IV). In a meta-analysis consisting of 17 studies investigating 8,371 cases and 12,574 control subjects, the overall results indicated that the genotypes of MTRR rs1801394 may be ethnically, associated with CRC risk, which means that Asian populations are more likely to be influenced by MTRR rs1801394 while Caucasian populations are not (44).

MTRR is one of the major players in folate metabolism, and plays essential roles in nucleotide neo-synthesis and methylation status of DNA, histones and proteins. The MTRR rs1801394 G/G genotype has been reported to have lower affinity with MTR (45). High folate intake may be a protective diet for CRC risk (46-48). However, all of these studies neither linked with personal MTRR genotype, nor assessed the dietary folate intake with the real serum folate status to reveal how folate influences CRC risk. The regulation of folate in serum is complicated, and lots of enzymes may be involved, for instance, MTHFR, MTRR and MTR. In 2018, we provided evidence for the significant association of MTHFR rs1801133 T allele serves as a predictive marker for CRC risk (49). It seems that those MTHFR rs1801394 G allele carriers can have a lower level of serum homo-cysteine, which by some unknown reason causes a higher efficiency in DNA repair activity, and keeps the human genome from instability and CRC carcinogenesis. The detailed mechanisms of how MTRR interact with other molecules leading to CRC needs further investigation in the future.

There have been various clinical or behavioral indexes reported to play a role in determining CRC risk, such as age, sex, familial cancer history, diet, alcohol consumption, obesity, tumor site, size, grade, histologic type, TNM stage, and carcinoembryonic antigen (CEA) level, and so on (50-53). But these kinds of epidemiological studies always lack genetic data for any genetic-linked analysis. In the present study, we combined numerous clinical indexes with genotyping data for analysis, and come up with the findings that MTRR rs1801394 G/G genotype can interact with non-smoking (Table V) and non-alcohol drinking habits (Table VI) to affect CRC risk. It is interesting, but complicated to figure out how MTRR rs1801394 G/G genotype can affect non-smokers and non-alcohol drinkers with their CRC risk, but not affect smokers and alcohol drinkers. We temporarily found no significant interactions between MTRR rs1801394 genotype and those clinical indexes (Table VII). However, some indexes such as tumor size (p=0.0664), may have significant results when larger sample size could be collected for bringing up a conclusive finding.

In conclusion, we provided evidence for the significant association of MTRR rs1801394 with Taiwan CRC risk. Our results also suggest that the G/G genotype of MTRR rs1801394 may have its protective effects specifically among non-smokers and non-alcohol drinkers. It can serve as a useful genomic marker for Taiwan CRC risk.

Acknowledgements

The Authors are grateful to Yu-Chen Hsiau and Yu-Ting Chin for their excellent technical assistance. All the participants including those who were not selected into the control group of the study are appreciated. This study was supported mainly by Taichung Armed Forces General Hospital (grant number: TCAFGH-D-110016), China Medical University and Hospital (grant number CMU110-ASIA-03) and Taichung Veterans General Hospital (grant number TCVGH-1115302B). The funders had no role in study design, data collection, statistical analysis, or decision to publish or preparation of the manuscript.

Footnotes

  • Authors’ Contributions

    Research design: Wu MH, Chen CH, Bau DT, Pei JS and Chang WS; patient and questionnaire summaries: Wu MH, Chen CP and Yueh TC; experimental work: Huang TH, Chang WS and Tsai CW; statistical analysis: Wang ZH, Mong MC and Yang YC; article writing: Chang WS and Bau DT; review and revision: Bau DT and Chang WS.

  • Conflicts of Interest

    The Authors declare no conflicts of interest regarding this study.

  • Received March 10, 2022.
  • Revision received March 31, 2022.
  • Accepted April 7, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Fuchs HE and
    4. Jemal A
    : Cancer statistics, 2022. CA Cancer J Clin 72(1): 7-33, 2022. PMID: 35020204. DOI: 10.3322/caac.21708
    OpenUrlCrossRefPubMed
  2. ↵
    1. Arnold M,
    2. Sierra MS,
    3. Laversanne M,
    4. Soerjomataram I,
    5. Jemal A and
    6. Bray F
    : Global patterns and trends in colorectal cancer incidence and mortality. Gut 66(4): 683-691, 2017. PMID: 26818619. DOI: 10.1136/gutjnl-2015-310912
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Siegel RL,
    2. Torre LA,
    3. Soerjomataram I,
    4. Hayes RB,
    5. Bray F,
    6. Weber TK and
    7. Jemal A
    : Global patterns and trends in colorectal cancer incidence in young adults. Gut 68(12): 2179-2185, 2019. PMID: 31488504. DOI: 10.1136/gutjnl-2019-319511
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Douaiher J,
    2. Ravipati A,
    3. Grams B,
    4. Chowdhury S,
    5. Alatise O and
    6. Are C
    : Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol 115(5): 619-630, 2017. PMID: 28194798. DOI: 10.1002/jso.24578
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nagini S
    : Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 4(7): 156-169, 2012. PMID: 22844547. DOI: 10.4251/wjgo.v4.i7.156
    OpenUrlCrossRefPubMed
  6. ↵
    1. Jayasurya R,
    2. Sathyan KM,
    3. Lakshminarayanan K,
    4. Abraham T,
    5. Nalinakumari KR,
    6. Abraham EK,
    7. Nair MK and
    8. Kannan S
    : Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol 18(8): 1056-1066, 2005. PMID: 15731778. DOI: 10.1038/modpathol.3800387
    OpenUrlCrossRefPubMed
  7. ↵
    1. Butterworth AS,
    2. Higgins JP and
    3. Pharoah P
    : Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 42(2): 216-227, 2006. PMID: 16338133. DOI: 10.1016/j.ejca.2005.09.023
    OpenUrlCrossRefPubMed
  8. ↵
    1. Houlston RS and
    2. Tomlinson IP
    : Polymorphisms and colorectal tumor risk. Gastroenterology 121(2): 282-301, 2001. PMID: 11487538. DOI: 10.1053/gast.2001.26265
    OpenUrlCrossRefPubMed
  9. ↵
    1. Wu MH,
    2. Tzeng HE,
    3. Wu CN,
    4. Yueh TC,
    5. Peng YC,
    6. Tsai CH,
    7. Wang YC,
    8. Ke TW,
    9. Pei JS,
    10. Chang WS,
    11. Tsai CW and
    12. Bau DT
    : Association of matrix metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk. Anticancer Res 39(12): 6523-6529, 2019. PMID: 31810917. DOI: 10.21873/anticanres.13867
    OpenUrlAbstract/FREE Full Text
    1. Wu MH,
    2. Hung YW,
    3. Gong CL,
    4. Chao CC,
    5. Yueh TC,
    6. Wang SC,
    7. Lai YL,
    8. Hsu SW,
    9. Fu CK,
    10. Wang YC,
    11. Ke TW,
    12. Chang WS,
    13. Tsai CW and
    14. Bau DT
    : Contribution of Caspase-8 genotypes to colorectal cancer risk in Taiwan. Anticancer Res 39(6): 2791-2797, 2019. PMID: 31177115. DOI: 10.21873/anticanres.13406
    OpenUrlAbstract/FREE Full Text
    1. Yueh TC,
    2. Hung YW,
    3. Shih TC,
    4. Wu CN,
    5. Wang SC,
    6. Lai YL,
    7. Hsu SW,
    8. Wu MH,
    9. Fu CK,
    10. Wang YC,
    11. Ke TW,
    12. Chang WS,
    13. Tsai CW and
    14. Bau DT
    : Contribution of murine double minute 2 genotypes to colorectal cancer risk in Taiwan. Cancer Genomics Proteomics 15(5): 405-411, 2018. PMID: 30194081. DOI: 10.21873/cgp.20099
    OpenUrlAbstract/FREE Full Text
    1. Yueh TC,
    2. Wu CN,
    3. Hung YW,
    4. Chang WS,
    5. Fu CK,
    6. Pei JS,
    7. Wu MH,
    8. Lai YL,
    9. Lee YM,
    10. Yen ST,
    11. Li HT,
    12. Tsai CW and
    13. Bau DT
    : The contribution of MMP-7 genotypes to colorectal cancer susceptibility in Taiwan. Cancer Genomics Proteomics 15(3): 207-212, 2018. PMID: 29695403. DOI: 10.21873/cgp.20079
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hung YC,
    2. Chang WS,
    3. Chou AK,
    4. Pei JS,
    5. Yang MD,
    6. Yang HR,
    7. Yang TM,
    8. Wang YC,
    9. Hsiau YC,
    10. Chen CP,
    11. Chen CC,
    12. Yu CC,
    13. Tsai CW and
    14. Bau DT
    : Association of Adiponectin genotypes with colorectal cancer susceptibility in Taiwan. Anticancer Res 40(3): 1297-1306, 2020. PMID: 32132026. DOI: 10.21873/anticanres.14071
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Wu MH,
    2. Yueh TC,
    3. Chang WS,
    4. Tsai CW,
    5. Fu CK,
    6. Yang MD,
    7. Yu CC and
    8. Bau DT
    : Contribution of Matrix Metalloproteinase-1 genotypes to colorectal cancer in Taiwan. Cancer Genomics Proteomics 18(3): 245-251, 2021. PMID: 33893077. DOI: 10.21873/cgp.20255
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Crider KS,
    2. Yang TP,
    3. Berry RJ and
    4. Bailey LB
    : Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role. Adv Nutr 3(1): 21-38, 2012. PMID: 22332098. DOI: 10.3945/an.111.000992
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Ly A,
    2. Hoyt L,
    3. Crowell J and
    4. Kim YI
    : Folate and DNA methylation. Antioxid Redox Signal 17(2): 302-326, 2012. PMID: 22332737. DOI: 10.1089/ars.2012.4554
    OpenUrlCrossRefPubMed
  14. ↵
    1. Li WX,
    2. Dai SX,
    3. Zheng JJ,
    4. Liu JQ and
    5. Huang JF
    : Homocysteine metabolism gene polymorphisms (MTHFR C677T, MTHFR A1298C, MTR A2756G and MTRR A66G) jointly elevate the risk of folate deficiency. Nutrients 7(8): 6670-6687, 2015. PMID: 26266420. DOI: 10.3390/nu7085303
    OpenUrlCrossRefPubMed
    1. Tsang BL,
    2. Devine OJ,
    3. Cordero AM,
    4. Marchetta CM,
    5. Mulinare J,
    6. Mersereau P,
    7. Guo J,
    8. Qi YP,
    9. Berry RJ,
    10. Rosenthal J,
    11. Crider KS and
    12. Hamner HC
    : Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and blood folate concentrations: a systematic review and meta-analysis of trials and observational studies. Am J Clin Nutr 101(6): 1286-1294, 2015. PMID: 25788000. DOI: 10.3945/ajcn.114.099994
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Durda K,
    2. Kąklewski K,
    3. Gupta S,
    4. Szydłowski M,
    5. Baszuk P,
    6. Jaworska-Bieniek K,
    7. Sukiennicki G,
    8. Kaczmarek K,
    9. Waloszczyk P,
    10. Narod S,
    11. Lubiński J and
    12. Jakubowska A
    : Serum folate concentration and the incidence of lung cancer. PLoS One 12(5): e0177441, 2017. PMID: 28493936. DOI: 10.1371/journal.pone.0177441
    OpenUrlCrossRefPubMed
  16. ↵
    1. Figueiredo JC,
    2. Levine AJ,
    3. Crott JW,
    4. Baurley J and
    5. Haile RW
    : Folate-genetics and colorectal neoplasia: what we know and need to know next. Mol Nutr Food Res 57(4): 607-627, 2013. PMID: 23401104. DOI: 10.1002/mnfr.201200278
    OpenUrlCrossRefPubMed
  17. ↵
    1. Williams EA
    : Folate, colorectal cancer and the involvement of DNA methylation. Proc Nutr Soc 71(4): 592-597, 2012. PMID: 22863281. DOI: 10.1017/S0029665112000717
    OpenUrlCrossRefPubMed
  18. ↵
    1. Leclerc D,
    2. Wilson A,
    3. Dumas R,
    4. Gafuik C,
    5. Song D,
    6. Watkins D,
    7. Heng HH,
    8. Rommens JM,
    9. Scherer SW,
    10. Rosenblatt DS and
    11. Gravel RA
    : Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 95(6): 3059-3064, 1998. PMID: 9501215. DOI: 10.1073/pnas.95.6.3059
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Chen J,
    2. Giovannucci E,
    3. Kelsey K,
    4. Rimm EB,
    5. Stampfer MJ,
    6. Colditz GA,
    7. Spiegelman D,
    8. Willett WC and
    9. Hunter DJ
    : A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 56(21): 4862-4864, 1996. PMID: 8895734.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Gaughan DJ,
    2. Kluijtmans LA,
    3. Barbaux S,
    4. McMaster D,
    5. Young IS,
    6. Yarnell JW,
    7. Evans A and
    8. Whitehead AS
    : The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 157(2): 451-456, 2001. PMID: 11472746. DOI: 10.1016/s0021-9150(00)00739-5
    OpenUrlCrossRefPubMed
  21. ↵
    1. Sharp L and
    2. Little J
    : Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 159(5): 423-443, 2004. PMID: 14977639. DOI: 10.1093/aje/kwh066
    OpenUrlCrossRefPubMed
  22. ↵
    1. Goelz SE,
    2. Vogelstein B,
    3. Hamilton SR and
    4. Feinberg AP
    : Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228(4696): 187-190, 1985. PMID: 2579435. DOI: 10.1126/science.2579435
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Duthie SJ
    : Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis 34(1): 101-109, 2011. PMID: 20544289. DOI: 10.1007/s10545-010-9128-0
    OpenUrlCrossRefPubMed
  24. ↵
    1. Pishva SR,
    2. Vasudevan R,
    3. Etemad A,
    4. Heidari F,
    5. Komara M,
    6. Ismail P,
    7. Othman F,
    8. Karimi A and
    9. Sabri MR
    : Analysis of MTHFR and MTRR gene polymorphisms in Iranian ventricular septal defect subjects. Int J Mol Sci 14(2): 2739-2752, 2013. PMID: 23358257. DOI: 10.3390/ijms14022739
    OpenUrlCrossRefPubMed
  25. ↵
    1. Su J and
    2. Li Z
    : Analysis of MTR and MTRR gene polymorphisms in Chinese patients with ventricular septal defect. Appl Immunohistochem Mol Morphol 26(10): 769-774, 2018. PMID: 29293099. DOI: 10.1097/PAI.0000000000000512
    OpenUrlCrossRefPubMed
  26. ↵
    1. Yuan L,
    2. Liu Z,
    3. Wei G,
    4. Yang P,
    5. Hu XE,
    6. Qu F,
    7. Lu J,
    8. He X and
    9. Bao G
    : Genetic polymorphisms in folate-metabolizing genes associated with gastric cancer prognosis in northwest China subjects. J Cancer 11(21): 6413-6420, 2020. PMID: 33033524. DOI: 10.7150/jca.46978
    OpenUrlCrossRefPubMed
  27. ↵
    1. Wei L,
    2. Niu F,
    3. Wu J,
    4. Chen F,
    5. Yang H,
    6. Li J,
    7. Jin T and
    8. Wu Y
    : Association study between genetic polymorphisms in folate metabolism and gastric cancer susceptibility in Chinese Han population: A case-control study. Mol Genet Genomic Med 7(5): e633, 2019. PMID: 30884202. DOI: 10.1002/mgg3.633
    OpenUrlCrossRefPubMed
  28. ↵
    1. Li CH,
    2. Yang YC,
    3. Hsia TC,
    4. Shen TC,
    5. Shen YC,
    6. Chang WS,
    7. Wang YC,
    8. Tsai CW and
    9. Bau DT
    : Association of Interleukin-8 promoter genotypes with Taiwan lung cancer risk. Anticancer Res 42(3): 1229-1236, 2022. PMID: 35220213. DOI: 10.21873/anticanres.15590
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Pei JS,
    2. Chang WS,
    3. Chen CC,
    4. Mong MC,
    5. Hsu SW,
    6. Hsu PC,
    7. Hsu YN,
    8. Wang YC,
    9. Tsai CW and
    10. Bau DT
    : Novel contribution of long non-coding RNA MEG3 genotype to prediction of childhood leukemia risk. Cancer Genomics Proteomics 19(1): 27-34, 2022. PMID: 34949657. DOI: 10.21873/cgp.20301
    OpenUrlAbstract/FREE Full Text
    1. Chang WS,
    2. Liu LC,
    3. Hsiao CL,
    4. Su CH,
    5. Wang HC,
    6. Ji HX,
    7. Tsai CW,
    8. Maa MC and
    9. Bau DT
    : The contributions of the tissue inhibitor of metalloproteinase-1 genotypes to triple negative breast cancer risk. Biomedicine (Taipei) 6(1): 4, 2016. PMID: 26872812. DOI: 10.7603/s40681-016-0004-6
    OpenUrlCrossRefPubMed
  30. ↵
    1. Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence
    : Cancer registration annual report. Available at: https://www.hpa.gov.tw/Pages/List.aspx?nodeid=269 [Last accessed on April 7, 2022]
  31. ↵
    1. Wettergren Y,
    2. Odin E,
    3. Carlsson G and
    4. Gustavsson B
    : MTHFR, MTR, and MTRR polymorphisms in relation to p16INK4A hypermethylation in mucosa of patients with colorectal cancer. Mol Med 16(9-10): 425-432, 2010. PMID: 20549016. DOI: 10.2119/molmed.2009.00156
    OpenUrlCrossRefPubMed
    1. Steck SE,
    2. Keku T,
    3. Butler LM,
    4. Galanko J,
    5. Massa B,
    6. Millikan RC and
    7. Sandler RS
    : Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyltransferase, folate and alcohol intake, and colon cancer risk. J Nutrigenet Nutrigenomics 1(4): 196-204, 2008. PMID: 19776626. DOI: 10.1159/000136651
    OpenUrlCrossRefPubMed
    1. Pardini B,
    2. Kumar R,
    3. Naccarati A,
    4. Prasad RB,
    5. Forsti A,
    6. Polakova V,
    7. Vodickova L,
    8. Novotny J,
    9. Hemminki K and
    10. Vodicka P
    : MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from the Czech Republic. Mutat Res 721(1): 74-80, 2011. PMID: 21211571. DOI: 10.1016/j.mrgentox.2010.12.008
    OpenUrlCrossRefPubMed
    1. Otani T,
    2. Iwasaki M,
    3. Hanaoka T,
    4. Kobayashi M,
    5. Ishihara J,
    6. Natsukawa S,
    7. Shaura K,
    8. Koizumi Y,
    9. Kasuga Y,
    10. Yoshimura K,
    11. Yoshida T and
    12. Tsugane S
    : Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital-based case-control study in Japan. Nutr Cancer 53(1): 42-50, 2005. PMID: 16351505. DOI: 10.1207/s15327914nc5301_5
    OpenUrlCrossRefPubMed
    1. Morita M,
    2. Yin G,
    3. Yoshimitsu S,
    4. Ohnaka K,
    5. Toyomura K,
    6. Kono S,
    7. Ueki T,
    8. Tanaka M,
    9. Kakeji Y,
    10. Maehara Y,
    11. Okamura T,
    12. Ikejiri K,
    13. Futami K,
    14. Maekawa T,
    15. Yasunami Y,
    16. Takenaka K,
    17. Ichimiya H and
    18. Terasaka R
    : Folate-related nutrients, genetic polymorphisms, and colorectal cancer risk: the fukuoka colorectal cancer study. Asian Pac J Cancer Prev 14(11): 6249-6256, 2013. PMID: 24377513. DOI: 10.7314/apjcp.2013.14.11.6249
    OpenUrlCrossRefPubMed
    1. Liu AY,
    2. Scherer D,
    3. Poole E,
    4. Potter JD,
    5. Curtin K,
    6. Makar K,
    7. Slattery ML,
    8. Caan BJ and
    9. Ulrich CM
    : Gene-diet-interactions in folate-mediated one-carbon metabolism modify colon cancer risk. Mol Nutr Food Res 57(4): 721-734, 2013. PMID: 22961839. DOI: 10.1002/mnfr.201200180
    OpenUrlCrossRefPubMed
    1. Koushik A,
    2. Kraft P,
    3. Fuchs CS,
    4. Hankinson SE,
    5. Willett WC,
    6. Giovannucci EL and
    7. Hunter DJ
    : Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev 15(12): 2408-2417, 2006. PMID: 17164363. DOI: 10.1158/1055-9965.EPI-06-0624
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Jokić M,
    2. Brčić-Kostić K,
    3. Stefulj J,
    4. Catela Ivković T,
    5. Božo L,
    6. Gamulin M and
    7. Kapitanović S
    : Association of MTHFR, MTR, MTRR, RFC1, and DHFR gene polymorphisms with susceptibility to sporadic colon cancer. DNA Cell Biol 30(10): 771-776, 2011. PMID: 21438757. DOI: 10.1089/dna.2010.1189
    OpenUrlCrossRefPubMed
  33. ↵
    1. Pabalan N,
    2. Singian E,
    3. Tabangay L,
    4. Jarjanazi H and
    5. Singh N
    : Associations of the A66G methionine synthase reductase polymorphism in colorectal cancer: a systematic review and meta-analysis. Biomark Cancer 7(Suppl 1): 21-28, 2015. PMID: 26549973. DOI: 10.4137/BIC.S25251
    OpenUrlCrossRefPubMed
  34. ↵
    1. Brown CA,
    2. McKinney KQ,
    3. Kaufman JS,
    4. Gravel RA and
    5. Rozen R
    : A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk 7(3): 197-200, 2000. PMID: 11006889. DOI: 10.1177/204748730000700306
    OpenUrlCrossRefPubMed
  35. ↵
    1. Sanjoaquin MA,
    2. Allen N,
    3. Couto E,
    4. Roddam AW and
    5. Key TJ
    : Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 113(5): 825-828, 2005. PMID: 15499620. DOI: 10.1002/ijc.20648
    OpenUrlCrossRefPubMed
    1. Tong SY,
    2. Lee JM,
    3. Song ES,
    4. Lee KB,
    5. Kim MK,
    6. Yun YM,
    7. Lee JK,
    8. Son SK,
    9. Lee JP,
    10. Kim JH,
    11. Hur SY and
    12. Kwon YI
    : The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. Cancer Causes Control 21(1): 23-30, 2010. PMID: 19760026. DOI: 10.1007/s10552-009-9430-z
    OpenUrlCrossRefPubMed
  36. ↵
    1. Kennedy DA,
    2. Stern SJ,
    3. Moretti M,
    4. Matok I,
    5. Sarkar M,
    6. Nickel C and
    7. Koren G
    : Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis. Cancer Epidemiol 35(1): 2-10, 2011. PMID: 21177150. DOI: 10.1016/j.canep.2010.11.004
    OpenUrlCrossRefPubMed
  37. ↵
    1. Lin KM,
    2. Yang MD,
    3. Tsai CW,
    4. Chang WS,
    5. Hsiao CL,
    6. Jeng LB,
    7. Yueh TC,
    8. Lee MC and
    9. Bau DT
    : The role of MTHFR genotype in colorectal cancer susceptibility in Taiwan. Anticancer Res 38(4): 2001-2006, 2018. PMID: 29599316. DOI: 10.21873/anticanres.12438
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Chen PC,
    2. Lee JC and
    3. Wang JD
    : Estimation of life-year loss and lifetime costs for different stages of colon adenocarcinoma in Taiwan. PLoS One 10(7): e0133755, 2015. PMID: 26207912. DOI: 10.1371/journal.pone.0133755
    OpenUrlCrossRefPubMed
    1. Beckmann KR,
    2. Bennett A,
    3. Young GP,
    4. Cole SR,
    5. Joshi R,
    6. Adams J,
    7. Singhal N,
    8. Karapetis C,
    9. Wattchow D and
    10. Roder D
    : Sociodemographic disparities in survival from colorectal cancer in South Australia: a population-wide data linkage study. BMC Health Serv Res 16: 24, 2016. PMID: 26792195. DOI: 10.1186/s12913-016-1263-3
    OpenUrlCrossRefPubMed
    1. Perron L,
    2. Daigle JM,
    3. Vandal N,
    4. Guertin MH and
    5. Brisson J
    : Characteristics affecting survival after locally advanced colorectal cancer in Quebec. Curr Oncol 22(6): e485-e492, 2015. PMID: 26715887. DOI: 10.3747/co.22.2692
    OpenUrlCrossRefPubMed
  39. ↵
    1. Wang R,
    2. Wang MJ and
    3. Ping J
    : Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: a population-based cohort study of SEER 9 registries data (1988-2011). Medicine (Baltimore) 94(35): e1402, 2015. PMID: 26334895. DOI: 10.1097/MD.0000000000001402
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (5)
Anticancer Research
Vol. 42, Issue 5
May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan
MING-HSIEN WU, CHAO-HSUAN CHEN, CHOU-PIN CHEN, TAI-LIN HUANG, TE-CHENG YUEH, ZHI-HONG WANG, CHIA-WEN TSAI, JEN-SHENG PEI, MEI-CHIN MONG, YA-CHEN YANG, DA-TIAN BAU, WEN-SHIN CHANG
Anticancer Research May 2022, 42 (5) 2375-2382; DOI: 10.21873/anticanres.15716

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan
MING-HSIEN WU, CHAO-HSUAN CHEN, CHOU-PIN CHEN, TAI-LIN HUANG, TE-CHENG YUEH, ZHI-HONG WANG, CHIA-WEN TSAI, JEN-SHENG PEI, MEI-CHIN MONG, YA-CHEN YANG, DA-TIAN BAU, WEN-SHIN CHANG
Anticancer Research May 2022, 42 (5) 2375-2382; DOI: 10.21873/anticanres.15716
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
  • Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer
  • Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer
Show more Experimental Studies

Similar Articles

Keywords

  • Colorectal cancer
  • genotype
  • MTRR
  • polymorphism
  • Taiwan
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire